SynCo To Make Acromegaly Drug for Syntaxin

SynCo Bio Partners B.V. has signed an agreement to produce Syntaxin’s novel drug candidate SXN101959. Syntaxin is developing SXN101959 for the therapeutic treatment of acromegaly as a primary indication. SynCo will assist Syntaxin in scale-up and manufacture of multiple batches of bulk drug substance and drug product of SXN101959 for non-clinical, Phase I and Phase II clinical trials.

In acromegaly, hypersecretion of growth hormone usually occurs from a benign pituitary tumour. Current first line therapy is the use of somatostatins, to reduce secretion; however, up to 60% of patients are refractory to this treatment so there is a significant unmet need for new products. Syntaxin’s Targeted Secretion Inhibitors (TSI) mechanism of action provides a unique and potentially superior approach to the inhibition of growth hormone release.

Pierre Warffemius, chief executive officer of SynCo Bio Partners, remarked, “SynCo is pleased to be working with Syntaxin on the manufacture of SXN101959 for the treatment of acromegaly. We aim to establish a long-term relationship with Syntaxin to support its unique TSI platform and expanding product portfolio, by providing high quality manufacturing and filling services.”

Dr, Melanie Lee, chief executive officer of Syntaxin, commented, “SynCo’s manufacturing capability provides us with the means to rapidly move SXN101959 through to Phase I clinical trials in acromegaly.”

Recently, Syntaxin’s partnered molecule AGN-214868 entered Phase II clinical trials in post-herpetic neuralgia (PHN).